- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its fourth quarter and year end financial results on Thursday, March 6, 2008. Results will be released at the close of trading on that day.
The announcement released earlier today by its former parent company, Acacia Research Corporation, regarding Acacia's earnings release has been erroneously reported by some news agencies as a CombiMatrix Corporation earnings announcement.
A conference call has also been scheduled regarding CombiMatrix Corporation's fourth quarter and year end earnings announcement. The presentation and Q&A session will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern) on Thursday, March 6, 2008.
To listen to the presentation by phone, dial 1-800-704-9804 for domestic callers, and 1-404-920-6604 for direct dial or international callers. All callers will need to provide the participant code 329443# (329443 followed by the # key). A replay of the audio presentation will be available for 14 days using the same dial-in numbers, but the participant code for the recorded playback is 641376# (641376 followed by the # key).
The call will be webcast live and can be accessed at CombiMatrix's website at www.combimatrix.com, in the Investor section.
About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology business having its focus on the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), a wholly owned subsidiary of the Company located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.
Additional information about CombiMatrix Corporation is available at www.combimatrix.com or call toll free: 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory, and competitive developments, and general economic conditions. Our Annual Report, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Amit Kumar, Ph.D., President & CEO,
Fax (425) 493-2010
Copyright © PrimeNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015
Industrial Nanotech, Inc. Provides Update June 8th, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015